- The FDA grants a CLIA waiver to Alere's (NYSE:ALR-OLD) i RSV test, cleared for marketing in the U.S. in August 2016. The waiver allows the test to be used in non-clinical laboratory settings such as a physician's office, a walk-in clinic or a hospital emergency room.
- It is the company's third test so designated.